Ventas, Inc. (VTR)
| Market Cap | 44.96B +47.4% |
| Revenue (ttm) | 6.42B +21.7% |
| Net Income | 262.73M +37.4% |
| EPS | 0.55 +27.7% |
| Shares Out | 516.39M |
| PE Ratio | 158.65 |
| Forward PE | 127.97 |
| Dividend | $2.08 (2.39%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | 510,077 |
| Open | 86.25 |
| Previous Close | 87.03 |
| Day's Range | 86.25 - 87.27 |
| 52-Week Range | 66.63 - 101.60 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 101.86 (+17.0%) |
| Earnings Date | Oct 28, 2026 |
About VTR
Ventas, Inc. is an S&P 500 company enabling exceptional environments that benefit a large and growing aging population. With approximately 1,450 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy. The Company’s growth is fueled by its more than 900 senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. Ventas aims to deliver outsized performance by leveraging its operational expertise, data-driven insights from its ... [Read more]
Financial Performance
In 2025, Ventas's revenue was $5.82 billion, an increase of 18.99% compared to the previous year's $4.89 billion. Earnings were $251.38 million, an increase of 209.76%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for VTR stock is "Buy." The 12-month stock price target is $101.86, which is an increase of 17.00% from the latest price.
News
Ventas price target lowered to $100 from $101 at Evercore ISI
Evercore ISI lowered the firm’s price target on Ventas (VTR) to $100 from $101 and keeps an Outperform rating on the shares. Adjustments to REIT valuations “reflect a careful recalibration…
Ventas assumed with a Buy at Jefferies
Jefferies analyst Joe Dickstein assumed coverage of Ventas (VTR) with a Buy rating and $102 price target The firm says senior housing remains its preferred way to invest in healthcare…
Ventas Declares Quarterly Dividend of $0.52 Per Common Share
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) today announced that its Board of Directors has declared a quarterly dividend of $0.52 per common share. The dividend will be payable in cash on Octo...
Ventas price target raised to $95 from $93 at Scotiabank
Scotiabank analyst Nicholas Yulico raised the firm’s price target on Ventas (VTR) to $95 from $93 and keeps a Sector Perform rating on the shares. The firm is updating its…
Ventas price target raised to $104 from $96 at Wells Fargo
Wells Fargo raised the firm’s price target on Ventas (VTR) to $104 from $96 and keeps an Overweight rating on the shares. The firm believes REITs will continue to fit…
Ventas price target raised to $102 from $99 at Barclays
Barclays raised the firm’s price target on Ventas (VTR) to $102 from $99 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the healthcare real…
Ventas Releases 2025-2026 Corporate Sustainability Report
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today announced the release of its 2025-2026 Corporate Sustainability Report (“CSR”). The report details the Company's co...
Ventas price target raised to $107 from $105 at BMO Capital
BMO Capital raised the firm’s price target on Ventas (VTR) to $107 from $105 and keeps an Outperform rating on the shares after the firm hosted investment-focused meetings with its…
Ventas price target raised to $72 from $67 at Citi
Citi raised the firm’s price target on Ventas (VTR) to $72 from $67 and keeps a Buy rating on the shares.
Ventas price target raised to $113 from $110 at BofA
BofA raised the firm’s price target on Ventas (VTR) to $113 from $110 and keeps a Buy rating on the shares. Despite earnings beats and FY26 estimate raises from three…
Ventas price target raised to $102 from $97 at Cantor Fitzgerald
Cantor Fitzgerald analyst Richard Anderson raised the firm’s price target on Ventas (VTR) to $102 from $97 and keeps an Overweight rating on the shares. Healthcare REIT results highlight strong…
Ventas Earnings Call Transcript: Q2 2026
Q2 2026 saw robust growth, with 10% same-property NOI and 18% SHOP NOI increases year-over-year. Full-year normalized FFO guidance was raised to $3.85–$3.90 per share, and SHOP is set to comprise 60% of the enterprise by year-end, reflecting strong investment momentum and demographic tailwinds.
Ventas Slides: Q2 2026
Ventas has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Ventas Earnings release: Q2 2026
Ventas released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Ventas Quarterly report: Q2 2026
Ventas has published its Q2 2026 quarterly earnings report on July 30, 2026.
Ventas reports Q2 FFO 97c, consensus 95c
Reports Q2 revenue $1.73B, consensus $1.68B. “Ventas’s (VTR) momentum continued in the second quarter. We delivered strong enterprise results, executing on our strategy to capture the unprecedented op...
Ventas raises FY26 normalized FFO view to $3.85-$3.90 from $3.82-$3.89
Consensus is $3.88.
Ventas Reports 2026 Second Quarter Results
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today reported results for the second quarter ended June 30, 2026. CEO Remarks “Ventas's momentum continued in the second...
Ventas price target raised to $104 from $98 at Mizuho
Mizuho raised the firm’s price target on Ventas (VTR) to $104 from $98 and keeps an Outperform rating on the shares. The firm adjusted targets in the healthcare real estate…
Ventas initiated with an Equal Weight at Barclays
Barclays analyst Richard Hightower initiated coverage of Ventas (VTR) with an Equal Weight rating and $99 price target While initiating coverage of six healthcare REITs, the analyst tells investors th...
Ventas Announces Second Quarter 2026 Earnings Release Date and Conference Call
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) will issue its second quarter 2026 earnings release after the close of trading on the New York Stock Exchange on Wednesday, July 29, 2026. A conferen...
Ventas Names Andrew L. Wattula EVP Outpatient Medical & Research
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today announced that the Company has named Andrew L. Wattula Executive Vice President, Outpatient Medical & Research and ...
Ventas price target lowered to $88 from $95 at Scotiabank
Scotiabank analyst Nicholas Yulico lowered the firm’s price target on Ventas (VTR) to $88 from $95 and keeps a Sector Perform rating on the shares. The firm sees real estate…
Ventas resumed with an Outperform at Raymond James
Raymond James resumed coverage of Ventas (VTR) with an Outperform rating and $94 price target The senior housing operator portfolio platform continues to deliver solid property-level performance throu...
Ventas price target raised to $100 from $95 at Deutsche Bank
Deutsche Bank analyst Omotayo Okusanya raised the firm’s price target on Ventas (VTR) to $100 from $95 and keeps a Buy rating on the shares after spending time with management.